JP2019506450A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506450A5
JP2019506450A5 JP2018556012A JP2018556012A JP2019506450A5 JP 2019506450 A5 JP2019506450 A5 JP 2019506450A5 JP 2018556012 A JP2018556012 A JP 2018556012A JP 2018556012 A JP2018556012 A JP 2018556012A JP 2019506450 A5 JP2019506450 A5 JP 2019506450A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
crospovidone
ibrutinib
sodium lauryl
lauryl sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506450A (ja
JP7336195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/050964 external-priority patent/WO2017125424A1/en
Publication of JP2019506450A publication Critical patent/JP2019506450A/ja
Publication of JP2019506450A5 publication Critical patent/JP2019506450A5/ja
Priority to JP2022063752A priority Critical patent/JP7565971B2/ja
Application granted granted Critical
Publication of JP7336195B2 publication Critical patent/JP7336195B2/ja
Priority to JP2024091441A priority patent/JP2024138243A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556012A 2016-01-19 2017-01-18 Ｂｔｋ阻害剤を含む製剤／組成物 Active JP7336195B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022063752A JP7565971B2 (ja) 2016-01-19 2022-04-07 Ｂｔｋ阻害剤を含む製剤／組成物
JP2024091441A JP2024138243A (ja) 2016-01-19 2024-06-05 Ｂｔｋ阻害剤を含む製剤／組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621001987 2016-01-19
IN201621001987 2016-01-19
PCT/EP2017/050964 WO2017125424A1 (en) 2016-01-19 2017-01-18 Formulations/compositions comprising a btk inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022063752A Division JP7565971B2 (ja) 2016-01-19 2022-04-07 Ｂｔｋ阻害剤を含む製剤／組成物

Publications (3)

Publication Number Publication Date
JP2019506450A JP2019506450A (ja) 2019-03-07
JP2019506450A5 true JP2019506450A5 (https=) 2020-02-27
JP7336195B2 JP7336195B2 (ja) 2023-08-31

Family

ID=57851068

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018556012A Active JP7336195B2 (ja) 2016-01-19 2017-01-18 Ｂｔｋ阻害剤を含む製剤／組成物
JP2022063752A Active JP7565971B2 (ja) 2016-01-19 2022-04-07 Ｂｔｋ阻害剤を含む製剤／組成物
JP2024091441A Pending JP2024138243A (ja) 2016-01-19 2024-06-05 Ｂｔｋ阻害剤を含む製剤／組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022063752A Active JP7565971B2 (ja) 2016-01-19 2022-04-07 Ｂｔｋ阻害剤を含む製剤／組成物
JP2024091441A Pending JP2024138243A (ja) 2016-01-19 2024-06-05 Ｂｔｋ阻害剤を含む製剤／組成物

Country Status (24)

Country Link
US (3) US20190290650A1 (https=)
EP (2) EP4663247A3 (https=)
JP (3) JP7336195B2 (https=)
KR (2) KR20250025518A (https=)
CN (2) CN114681462A (https=)
AR (1) AR107392A1 (https=)
AU (1) AU2017208473B2 (https=)
BR (1) BR112018014540B1 (https=)
DK (1) DK3405178T3 (https=)
EA (1) EA201891664A1 (https=)
ES (1) ES3041841T3 (https=)
FI (1) FI3405178T3 (https=)
HK (2) HK1259441A1 (https=)
HR (1) HRP20251152T1 (https=)
LT (1) LT3405178T (https=)
MA (1) MA43650B1 (https=)
MX (2) MX2018008772A (https=)
PL (1) PL3405178T3 (https=)
PT (1) PT3405178T (https=)
RS (1) RS67236B1 (https=)
SI (1) SI3405178T1 (https=)
SM (1) SMT202500360T1 (https=)
TW (1) TWI794153B (https=)
WO (1) WO2017125424A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20190290650A1 (en) * 2016-01-19 2019-09-26 Janssen Pharmaceutic Nv Formulations/compositions comprising a btk inhibitor
EP3523280B1 (en) 2016-10-06 2026-03-11 Janssen Pharmaceutica NV Processes and intermediates for preparing a btk inhibitor
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3089537A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
BR112020024481A2 (pt) 2018-06-15 2021-03-02 Janssen Pharmaceutica Nv formulações/composições compreendendo ibrutinib
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
AU2020370039B2 (en) * 2019-10-21 2026-02-19 Celgene Corporation Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
US20250360130A1 (en) * 2024-05-21 2025-11-27 Telios Pharma Inc. Methods of treating indolent systemic mastocytosis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
MX391121B (es) * 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
HK1224173A1 (zh) * 2013-03-14 2017-08-18 Pharmacyclics Llc 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
MX2018008771A (es) * 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.
US20190290650A1 (en) * 2016-01-19 2019-09-26 Janssen Pharmaceutic Nv Formulations/compositions comprising a btk inhibitor

Similar Documents

Publication Publication Date Title
JP2019506450A5 (https=)
JP2019506387A5 (https=)
ES3048688T3 (en) High dosage strength tablets of rucaparib
JP2021501142A (ja) キナーゼを調節する化合物の製剤
KR101578481B1 (ko) 증식성 질환을 치료하기 위하여 ｎ－（5－ｔｅｒｔ－부틸－아이소제이졸－3－일）－ｎ′－｛4－［7－（2－몰포린－4－일－에톡시）이미다조［2,1－ｂ］［1,3］벤조티아졸－2－일］페닐｝우레아를 투여하는 방법
EP3383433A1 (en) Methods of treatment of malignancies
FI3405178T3 (fi) Btk:n estäjää käsittäviä formulaatioita/koostumuksia
EA025198B1 (ru) Фармацевтическая таблетка, способ её получения и способ лечения рака
WO2012164578A1 (en) Compositions and methods for preparing immediate release formulations of nilotinib
WO2015189386A1 (en) Composition with a high drug load of sofosbuvir
KR20190045199A (ko) 정제 조성물
JP2023065568A (ja) 異常な細胞成長を処置するための組成物および方法
US20070172521A1 (en) Levetiracetam formulations and methods for their manufacture
JP2019535696A (ja) ピリドン誘導体の医薬組成物およびその製造方法
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
JP7675724B2 (ja) ピラゾール医薬組成物
EP2644197A1 (en) Novel Pharmaceutical Compositions of Entecavir
WO2019171394A1 (en) Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
KR20240012436A (ko) 복수의 타스퀴니모드 입자 및 그 용도
KR101476096B1 (ko) 용해도가 향상된 쎄레콕시브의 약제학적 조성물
EP2644196B1 (en) Pharmaceutical compositions of Entecavir
CN114786670B (zh) 一种药物口服剂型
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib
JP7115825B2 (ja) エゼチミブ含有経口製剤及びその製造方法
KR20250101196A (ko) 생체 이용률이 개선된 페노피브레이트를 포함하는 약제학적 조성물